“…[ 8 , 9 , 10 ] The convenience of oral Ins may encourage earlier initiation of Ins therapy, improve patient compliance, and ultimately lead to better glucose control and long‐term outcomes. [ 11 ] Nevertheless, being similar to many protein components, oral Ins still faces significant challenges such as poor gastrointestinal stability, [ 12 , 13 , 14 ] rapid metabolism, [ 15 , 16 , 17 ] quick systemic elimination, and both easy aggregation and difficult absorption face great challenges. [ 18 , 19 , 20 ] Which leads to low therapeutic efficiency.…”